What is the present valuation and projected CAGR of the rubella diagnostic testing market?
The rubella diagnostic testing market size has grown strongly in recent years. It will grow from $1.3 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to a rise in vaccination programs, a rising incidence of immunization-preventable outbreaks, government initiatives to combat the rubella virus, and the expansion of diagnostic testing in non-traditional settings.
The rubella diagnostic testing market size is expected to see strong growth in the next few years. It will grow to $1.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing healthcare expenditure, growing focus on preventive healthcare, rising awareness of vaccine-preventable diseases, growing public health campaigns, and expansion of telemedicine and remote diagnostics. Major trends in the forecast period include advancements in diagnostic technologies, technological integration in healthcare systems, development of point-of-care testing solutions, development of new diagnostic methods, and advancements in molecular diagnostics.
Get Your Free Sample of The Global Rubella Diagnostic Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19177&type=smp
What key drivers have fueled the rubella diagnostic testing market’s development over the years?
The rising cases of viral infections are expected to propel the growth of the rubella diagnostic testing market going forward. Viral infections are illnesses caused by viruses, tiny infectious agents that can only replicate inside the living cells of an organism. The rising cases of viral infections are due to increased global travel, which facilitates the spread of viruses across borders, and climate change, which alters vector habitats and extends the range of disease-carrying organisms. Rubella diagnostic testing helps identify and manage rubella infections early, preventing complications, particularly in pregnant women, and aiding in outbreak control to reduce virus spread. For instance, in December 2023, according to the National Health Service, a UK-based government department, the number of daily hospital admissions for flu averaged 234, marking a 53% increase from the previous week, while hospital cases of norovirus rose by 15% to an average of 406 daily, reflecting a 28% increase from the same week last year. Therefore, the rising cases of viral infections are driving the growth of the rubella diagnostic testing market.
What is the segmentation for the rubella diagnostic testing market?
The rubella diagnostic testingmarket covered in this report is segmented –
1) By Diagnostic Technique: Latex Agglutination, Liver Function Tests, Enzyme Immunoassay (EIA), Radioimmunoassay (Ria), Fluorescent Immunoassay (FIA), Other Diagnostic Techniques
2) By Age Group: Neonates, Teenagers, Adults
3) By End User: Hospitals And Clinics, Cancer Diagnostic Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Latex Agglutination: Qualitative Latex Agglutination Tests, Quantitative Latex Agglutination Tests, Rapid Latex Agglutination Kits
2) By Liver Function Tests: Serum Bilirubin Tests, Alanine Aminotransferase (ALT) Tests, Aspartate Aminotransferase (AST) Tests, Alkaline Phosphatase (ALP) Tests, Other Liver Enzyme Tests
3) By Enzyme Immunoassay (EIA): Direct EIA, Indirect EIA, Sandwich EIA, Competitive EIA
4) By Radioimmunoassay (RIA): Standard RIA, Modified RIA, Single-Antibody RIA
5) By Fluorescent Immunoassay (FIA): Direct FIA, Indirect FIA, Sandwich FIA
6) Other Diagnostic Techniques: Polymerase Chain Reaction (PCR), Nucleic Acid Amplification Tests (NAAT), Microplate-Based Assays, Western Blotting
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/rubella-diagnostic-testing-global-market-report
Who are the most influential companies in the rubella diagnostic testing market?
Major companies operating in the rubella diagnostic testing market are Cardinal Health Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., bioMérieux S.A., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., Meridian Bioscience Inc., Fortress Diagnostics Ltd., Mylab Discovery Solutions Pvt. Ltd., MP Biomedicals LLC, CTK Biotech Inc., ZEUS Scientific Inc., Creative Diagnostics, Arlington Scientific Inc., AccuBioTech Co. Ltd., Intec Products Inc., Vitrosens Biotechnology Ltd., Sprint Diagnostics Pvt. Ltd., InDevR Inc., Atlas Medical GmbH
What are the top industry trends projected to impact the rubella diagnostic testing market?
Major companies operating in the rubella diagnostic testing market are focusing on developing innovative solutions, such as a rubella virus vaccine, to enhance diagnostic accuracy and improve preventive measures. The rubella virus vaccine is a vaccine that provides immunity against rubella, often administered as part of the MMR or MMRV combination vaccines to prevent the disease and associated complications. For instance, in March 2023, Merck & Co., Inc., a US-based pharmaceutical company, received FDA approval for the intramuscular (IM) administration of Merck’s M-M-R II vaccine, which is crucial in protecting against rubella, along with measles and mumps. This approval allows healthcare providers to administer the rubella vaccine using the IM route, making it consistent with other routinely recommended pediatric vaccines. Rubella vaccination is essential for preventing outbreaks and protecting against the severe complications the virus can cause, particularly in pregnant women.
What are the major regional insights for the rubella diagnostic testing market, and which region holds the top position?
North America was the largest region in the rubella diagnostic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rubella diagnostic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Rubella Diagnostic Testing Market Report 2025 Offer?
The rubella diagnostic testing market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Rubella diagnostic testing refers to the methods used to detect the presence of rubella virus or antibodies in a patient’s blood to confirm if they have been infected with rubella or have immunity against it. These tests help healthcare providers diagnose rubella accurately and manage its implications, especially in vulnerable populations.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19177
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
